Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.8915 |
High Similarity |
NPD3027 |
Phase 3 |
0.845 |
Intermediate Similarity |
NPD2983 |
Phase 2 |
0.845 |
Intermediate Similarity |
NPD2982 |
Phase 2 |
0.8372 |
Intermediate Similarity |
NPD2981 |
Phase 2 |
0.8346 |
Intermediate Similarity |
NPD1357 |
Approved |
0.8271 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.8195 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.8195 |
Intermediate Similarity |
NPD3018 |
Phase 2 |
0.8168 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.8162 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.8162 |
Intermediate Similarity |
NPD1613 |
Approved |
0.8154 |
Intermediate Similarity |
NPD3705 |
Approved |
0.8145 |
Intermediate Similarity |
NPD228 |
Approved |
0.8013 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7919 |
Intermediate Similarity |
NPD37 |
Approved |
0.7891 |
Intermediate Similarity |
NPD1653 |
Approved |
0.7874 |
Intermediate Similarity |
NPD5283 |
Phase 1 |
0.7862 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7823 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7763 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7763 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7763 |
Intermediate Similarity |
NPD4966 |
Approved |
0.774 |
Intermediate Similarity |
NPD4357 |
Discontinued |
0.7692 |
Intermediate Similarity |
NPD7266 |
Discontinued |
0.7677 |
Intermediate Similarity |
NPD7199 |
Phase 2 |
0.7658 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7658 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7647 |
Intermediate Similarity |
NPD3882 |
Suspended |
0.7634 |
Intermediate Similarity |
NPD5536 |
Phase 2 |
0.7632 |
Intermediate Similarity |
NPD2978 |
Approved |
0.7632 |
Intermediate Similarity |
NPD2977 |
Approved |
0.7623 |
Intermediate Similarity |
NPD1242 |
Phase 1 |
0.7612 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7609 |
Intermediate Similarity |
NPD4908 |
Phase 1 |
0.758 |
Intermediate Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.7576 |
Intermediate Similarity |
NPD1548 |
Phase 1 |
0.7569 |
Intermediate Similarity |
NPD3540 |
Phase 1 |
0.7559 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7559 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7518 |
Intermediate Similarity |
NPD1558 |
Phase 1 |
0.7516 |
Intermediate Similarity |
NPD2801 |
Approved |
0.75 |
Intermediate Similarity |
NPD7054 |
Approved |
0.75 |
Intermediate Similarity |
NPD3539 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.7481 |
Intermediate Similarity |
NPD1610 |
Phase 2 |
0.7453 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7453 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7451 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7394 |
Intermediate Similarity |
NPD3620 |
Phase 2 |
0.7394 |
Intermediate Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.732 |
Intermediate Similarity |
NPD4675 |
Approved |
0.732 |
Intermediate Similarity |
NPD4678 |
Approved |
0.7305 |
Intermediate Similarity |
NPD4625 |
Phase 3 |
0.7301 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.729 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7267 |
Intermediate Similarity |
NPD1511 |
Approved |
0.7261 |
Intermediate Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.7256 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7254 |
Intermediate Similarity |
NPD3144 |
Approved |
0.7254 |
Intermediate Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.7254 |
Intermediate Similarity |
NPD3145 |
Approved |
0.7248 |
Intermediate Similarity |
NPD2219 |
Phase 1 |
0.7248 |
Intermediate Similarity |
NPD5307 |
Clinical (unspecified phase) |
0.7246 |
Intermediate Similarity |
NPD4749 |
Approved |
0.723 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.723 |
Intermediate Similarity |
NPD3060 |
Approved |
0.723 |
Intermediate Similarity |
NPD4237 |
Approved |
0.723 |
Intermediate Similarity |
NPD4236 |
Phase 3 |
0.7226 |
Intermediate Similarity |
NPD422 |
Phase 1 |
0.7222 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7213 |
Intermediate Similarity |
NPD9296 |
Approved |
0.7212 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7212 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7203 |
Intermediate Similarity |
NPD2674 |
Phase 3 |
0.72 |
Intermediate Similarity |
NPD7124 |
Phase 2 |
0.72 |
Intermediate Similarity |
NPD5058 |
Phase 3 |
0.7197 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7171 |
Intermediate Similarity |
NPD1512 |
Approved |
0.7163 |
Intermediate Similarity |
NPD2861 |
Phase 2 |
0.7163 |
Intermediate Similarity |
NPD9494 |
Approved |
0.7153 |
Intermediate Similarity |
NPD4060 |
Phase 1 |
0.7152 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7152 |
Intermediate Similarity |
NPD5297 |
Approved |
0.7143 |
Intermediate Similarity |
NPD4005 |
Discontinued |
0.7134 |
Intermediate Similarity |
NPD3817 |
Phase 2 |
0.7122 |
Intermediate Similarity |
NPD3600 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7099 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7095 |
Intermediate Similarity |
NPD1375 |
Discontinued |
0.7092 |
Intermediate Similarity |
NPD6917 |
Clinical (unspecified phase) |
0.7081 |
Intermediate Similarity |
NPD6232 |
Discontinued |
0.7077 |
Intermediate Similarity |
NPD2684 |
Approved |
0.7055 |
Intermediate Similarity |
NPD2492 |
Phase 1 |
0.7048 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7048 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7044 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.7044 |
Intermediate Similarity |
NPD5604 |
Discontinued |
0.7032 |
Intermediate Similarity |
NPD6055 |
Clinical (unspecified phase) |
0.7025 |
Intermediate Similarity |
NPD6374 |
Clinical (unspecified phase) |
0.702 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7014 |
Intermediate Similarity |
NPD6410 |
Clinical (unspecified phase) |
0.7008 |
Intermediate Similarity |
NPD846 |
Approved |
0.7008 |
Intermediate Similarity |
NPD940 |
Approved |
0.7007 |
Intermediate Similarity |
NPD6111 |
Discontinued |
0.6993 |
Remote Similarity |
NPD4123 |
Phase 3 |
0.6992 |
Remote Similarity |
NPD7843 |
Approved |
0.6987 |
Remote Similarity |
NPD7028 |
Phase 2 |
0.6982 |
Remote Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.6966 |
Remote Similarity |
NPD554 |
Clinical (unspecified phase) |
0.6963 |
Remote Similarity |
NPD7157 |
Approved |
0.6962 |
Remote Similarity |
NPD5563 |
Clinical (unspecified phase) |
0.6951 |
Remote Similarity |
NPD7473 |
Discontinued |
0.695 |
Remote Similarity |
NPD2922 |
Phase 1 |
0.6948 |
Remote Similarity |
NPD1940 |
Clinical (unspecified phase) |
0.6944 |
Remote Similarity |
NPD7095 |
Approved |
0.6935 |
Remote Similarity |
NPD2933 |
Approved |
0.6935 |
Remote Similarity |
NPD2934 |
Approved |
0.6923 |
Remote Similarity |
NPD968 |
Approved |
0.6918 |
Remote Similarity |
NPD1240 |
Approved |
0.6908 |
Remote Similarity |
NPD5084 |
Clinical (unspecified phase) |
0.6897 |
Remote Similarity |
NPD5109 |
Approved |
0.6897 |
Remote Similarity |
NPD5111 |
Phase 2 |
0.6897 |
Remote Similarity |
NPD5110 |
Phase 2 |
0.6894 |
Remote Similarity |
NPD4750 |
Phase 3 |
0.688 |
Remote Similarity |
NPD2860 |
Approved |
0.688 |
Remote Similarity |
NPD2859 |
Approved |
0.6875 |
Remote Similarity |
NPD291 |
Approved |
0.6875 |
Remote Similarity |
NPD5752 |
Clinical (unspecified phase) |
0.687 |
Remote Similarity |
NPD290 |
Approved |
0.687 |
Remote Similarity |
NPD1358 |
Approved |
0.6863 |
Remote Similarity |
NPD6783 |
Clinical (unspecified phase) |
0.6855 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6853 |
Remote Similarity |
NPD6584 |
Phase 3 |
0.685 |
Remote Similarity |
NPD3020 |
Approved |
0.6849 |
Remote Similarity |
NPD1726 |
Clinical (unspecified phase) |
0.6846 |
Remote Similarity |
NPD5588 |
Approved |
0.6846 |
Remote Similarity |
NPD1510 |
Phase 2 |
0.6846 |
Remote Similarity |
NPD4108 |
Discontinued |
0.6842 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.6842 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6838 |
Remote Similarity |
NPD709 |
Approved |
0.6838 |
Remote Similarity |
NPD6671 |
Approved |
0.6836 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.6835 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6835 |
Remote Similarity |
NPD5126 |
Approved |
0.6832 |
Remote Similarity |
NPD4055 |
Discovery |
0.6824 |
Remote Similarity |
NPD1607 |
Approved |
0.6821 |
Remote Similarity |
NPD970 |
Clinical (unspecified phase) |
0.6818 |
Remote Similarity |
NPD6799 |
Approved |
0.6815 |
Remote Similarity |
NPD7261 |
Clinical (unspecified phase) |
0.6803 |
Remote Similarity |
NPD943 |
Approved |
0.68 |
Remote Similarity |
NPD2935 |
Discontinued |
0.68 |
Remote Similarity |
NPD3454 |
Phase 3 |
0.6792 |
Remote Similarity |
NPD3383 |
Approved |
0.6792 |
Remote Similarity |
NPD3384 |
Approved |
0.6792 |
Remote Similarity |
NPD3382 |
Approved |
0.6786 |
Remote Similarity |
NPD3847 |
Discontinued |
0.6781 |
Remote Similarity |
NPD5718 |
Phase 2 |
0.6779 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6779 |
Remote Similarity |
NPD4538 |
Approved |
0.6779 |
Remote Similarity |
NPD4536 |
Approved |
0.6778 |
Remote Similarity |
NPD7680 |
Approved |
0.6776 |
Remote Similarity |
NPD5177 |
Phase 3 |
0.6776 |
Remote Similarity |
NPD4162 |
Approved |
0.6776 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6776 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6774 |
Remote Similarity |
NPD7447 |
Phase 1 |
0.6774 |
Remote Similarity |
NPD4378 |
Clinical (unspecified phase) |
0.6772 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6768 |
Remote Similarity |
NPD4606 |
Clinical (unspecified phase) |
0.6767 |
Remote Similarity |
NPD556 |
Approved |
0.6767 |
Remote Similarity |
NPD5451 |
Approved |
0.6766 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6766 |
Remote Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.6757 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6757 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6757 |
Remote Similarity |
NPD1933 |
Approved |
0.6755 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6748 |
Remote Similarity |
NPD5494 |
Approved |
0.6741 |
Remote Similarity |
NPD5535 |
Approved |
0.6735 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6732 |
Remote Similarity |
NPD4628 |
Phase 3 |
0.6732 |
Remote Similarity |
NPD3892 |
Phase 2 |
0.6732 |
Remote Similarity |
NPD3750 |
Approved |
0.6732 |
Remote Similarity |
NPD6331 |
Phase 2 |
0.6731 |
Remote Similarity |
NPD5261 |
Clinical (unspecified phase) |
0.6728 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6725 |
Remote Similarity |
NPD8054 |
Approved |
0.6725 |
Remote Similarity |
NPD8053 |
Approved |
0.6721 |
Remote Similarity |
NPD9094 |
Approved |
0.6716 |
Remote Similarity |
NPD9280 |
Clinical (unspecified phase) |
0.6714 |
Remote Similarity |
NPD4626 |
Approved |
0.6714 |
Remote Similarity |
NPD5846 |
Approved |
0.6714 |
Remote Similarity |
NPD6516 |
Phase 2 |
0.6713 |
Remote Similarity |
NPD8651 |
Approved |
0.6711 |
Remote Similarity |
NPD1772 |
Clinical (unspecified phase) |
0.671
|
Remote Similarity |
NPD7212 |
Phase 2 |